Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,046.00
Bid: 12,044.00
Ask: 12,048.00
Change: -110.00 (-0.90%)
Spread: 4.00 (0.033%)
Open: 12,092.00
High: 12,098.00
Low: 12,036.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Block listing Interim Review

1 Dec 2021 15:00

RNS Number : 2427U
AstraZeneca PLC
01 December 2021
 

1 December 2021 15:00 GMT

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

(Note: Italicised terms have the same meaning as given in the Listing Rules.)

 

Date: 1 December 2021

 

Name of applicant:

ASTRAZENECA PLC

Name of scheme:

ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE OPTION PLAN; ASTRAZENECA ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED SHARE OPTION SCHEME

Period of return:

From:

1 JUNE 2021

To:

30 NOVEMBER 2021

Balance of unallotted securities under scheme(s) from previous return:

5,252,778

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

65,397

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

5,187,381

 

Name of contact:

Hannah Tattersall

Telephone number of contact:

+44 (0)746 498 2582

 

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

 

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

 

 

 

Adrian KempCompany Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRFSLFEFEFSEEE
Date   Source Headline
5th Sep 20227:05 amRNSForxiga approved in China for CKD
5th Sep 20227:00 amRNSImfinzi approved in US for biliary tract cancer
1st Sep 20223:00 pmRNSTotal Voting Rights
30th Aug 20221:00 pmRNSEvusheld approved for COVID-19 in Japan
30th Aug 20227:01 amRNSFarxiga shows CV mortality benefit across EF range
30th Aug 20227:00 amRNSFarxiga reduced risk of CV death or worsening HF
25th Aug 20227:10 amRNSUltomiris approved in Japan for gMG
25th Aug 20227:05 amRNSTagrisso approved in Japan for early lung cancer
25th Aug 20227:00 amRNSLynparza approved in Japan for early breast cancer
16th Aug 20227:00 amRNSLynparza granted FDA priority review for PROpel
15th Aug 20227:00 amRNSEnhertu improved PFS in mBC in DESTINY-Breast02
12th Aug 20227:00 amRNSEnhertu approved in US for HER2-mutant NSCLC
11th Aug 20227:00 amRNSAcquisition of TeneoTwo completed
8th Aug 20227:10 amRNSEnhertu approved in the US for HER2-low mBC
4th Aug 20227:00 amRNSLynparza approved in EU for early breast cancer
1st Aug 20225:00 pmRNSDirector/PDMR Shareholding
1st Aug 20223:05 pmRNSDirector/PDMR Shareholding
1st Aug 20223:00 pmRNSTotal Voting Rights
29th Jul 20227:01 amRNSChair succession
29th Jul 20227:00 amRNSHalf-year Report
25th Jul 20227:10 amRNSTezspire recommended for EU approval in asthma
25th Jul 20227:05 amRNSUltomiris recommended for EU approval for gMG
25th Jul 20227:00 amRNSEnhertu granted Priority Review for HER2-low mBC
19th Jul 20227:00 amRNSEnhertu approved in EU for HER2-positive mBC
5th Jul 20227:00 amRNSAstraZeneca to acquire TeneoTwo and T cell engager
1st Jul 20223:00 pmRNSTotal Voting Rights
30th Jun 20227:00 amRNSImfinzi improved pCR in resectable lung cancer
27th Jun 20227:05 amRNSEnhertu recommended for breast cancer EU approval
27th Jun 20227:00 amRNSLynparza recommended in EU for early breast cancer
21st Jun 20227:00 amRNSEplontersen Ph III trial met co-primary endpoints
6th Jun 20227:00 amRNSEnhertu efficacy results in HER2-low breast cancer
1st Jun 20223:00 pmRNSBlock listing Interim Review
1st Jun 20223:00 pmRNSTotal Voting Rights
20th May 20224:00 pmRNSDirector/PDMR Shareholding
9th May 20221:00 pmRNSAppointment of joint corporate brokers
6th May 20224:00 pmRNSDirector/PDMR Shareholding
5th May 20227:10 amRNSEnhertu approved in US for 2L HER2+ breast cancer
5th May 20227:05 amRNSFarxiga HFpEF Phase III trial met primary endpoint
5th May 20227:00 amRNSUltomiris NMOSD Ph. III trial met primary endpoint
4th May 20227:00 amRNSImfinzi combo granted Priority Review for BTC
3rd May 20223:00 pmRNSTotal Voting Rights
29th Apr 20225:30 pmRNSResult of AGM
29th Apr 20227:05 amRNSAstraZeneca plans new R&D centre in Massachusetts
29th Apr 20227:00 amRNSFirst quarter 2022 results
28th Apr 20227:00 amRNSUltomiris approved in the US for adults with gMG
27th Apr 20227:00 amRNSEnhertu granted BTD for HER2-low breast cancer
25th Apr 20227:00 amRNSTremelimumab US Priority Review for Imfinzi combo
19th Apr 20227:00 amRNSEnhertu granted Priority Review for HER2m NSCLC
1st Apr 20223:00 pmRNSTotal Voting Rights
29th Mar 20227:00 amRNSOndexxya approved in Japan for FXai reversal

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.